dc.contributor.author | González Cano, Rafael | |
dc.contributor.author | Ruiz Cantero, María del Carmen | |
dc.contributor.author | Santos Caballero, Miriam | |
dc.contributor.author | Gómez Navas, Carlos | |
dc.contributor.author | Nieto López, Francisco Rafael | |
dc.date.accessioned | 2021-09-21T06:58:48Z | |
dc.date.available | 2021-09-21T06:58:48Z | |
dc.date.issued | 2021-07-12 | |
dc.identifier.citation | González-Cano, R... [et al.]. Tetrodotoxin, a Potential Drug for Neuropathic and Cancer Pain Relief? Toxins 2021, 13, 483. [https://doi.org/10.3390/toxins13070483] | es_ES |
dc.identifier.uri | http://hdl.handle.net/10481/70310 | |
dc.description | This publication was partially supported by grant CTS 109 from the Junta de Andalucia, grant INTRAIBS-2020-09 from Biosanitary Research Institute ibs.GRANADA, and grant PPJIA2020-06 from the University of Granada. | es_ES |
dc.description.abstract | Tetrodotoxin (TTX) is a potent neurotoxin found mainly in puffer fish and other marine and
terrestrial animals. TTX blocks voltage-gated sodium channels (VGSCs) which are typically classified
as TTX-sensitive or TTX-resistant channels. VGSCs play a key role in pain signaling and some
TTX-sensitive VGSCs are highly expressed by adult primary sensory neurons. During pathological
pain conditions, such as neuropathic pain, upregulation of some TTX-sensitive VGSCs, including the
massive re-expression of the embryonic VGSC subtype NaV1.3 in adult primary sensory neurons,
contribute to painful hypersensitization. In addition, people with loss-of-function mutations in the
VGSC subtype NaV1.7 present congenital insensitive to pain. TTX displays a prominent analgesic
effect in several models of neuropathic pain in rodents. According to this promising preclinical
evidence, TTX is currently under clinical development for chemo-therapy-induced neuropathic pain
and cancer-related pain. This review focuses primarily on the preclinical and clinical evidence that
support a potential analgesic role for TTX in these pain states. In addition, we also analyze the
main toxic effects that this neurotoxin produces when it is administered at therapeutic doses, and
the therapeutic potential to alleviate neuropathic pain of other natural toxins that selectively block
TTX-sensitive VGSCs. | es_ES |
dc.description.sponsorship | Junta de Andalucia CTS 109 | es_ES |
dc.description.sponsorship | Biosanitary Research Institute ibs.GRANADA INTRAIBS-2020-09 | es_ES |
dc.description.sponsorship | University of Granada PPJIA2020-06 | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | MDPI | es_ES |
dc.rights | Atribución 3.0 España | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.subject | Tetrodotoxin | es_ES |
dc.subject | TTX | es_ES |
dc.subject | Voltage-gated sodium channels | es_ES |
dc.subject | Neuropathic pain | es_ES |
dc.subject | Cancer pain | es_ES |
dc.title | Tetrodotoxin, a Potential Drug for Neuropathic and Cancer Pain Relief? | es_ES |
dc.type | journal article | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.identifier.doi | 10.3390/toxins13070483 | |
dc.type.hasVersion | VoR | es_ES |